• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Vaginal Cancer - Pipeline Review, H2 2012 Product Image

Vaginal Cancer - Pipeline Review, H2 2012

  • ID: 2335237
  • November 2012
  • 33 pages
  • Global Markets Direct

Vaginal Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Vaginal Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vaginal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Cancer. Vaginal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vaginal Cancer.
- A review of the Vaginal Cancer products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Vaginal Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vaginal Cancer 7
Vaginal Cancer Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Vaginal Cancer Therapeutics – Products under Investigation by Universities/Institutes 12
Vaginal Cancer – Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Combination Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
Vinorelbine + Paclitaxel + Radiation Therapy - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Avastin + Radiation Therapy - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
docetaxel - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Triapine + Cisplatin + Radiation Therapy - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
topotecan hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Carboplatin + Gemcitabine Hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Vaginal Cancer Therapeutics – Discontinued Products 28
Vaginal Cancer Therapeutics - Dormant Products 29
Vaginal Cancer – Product Development Milestones 30
Featured News & Press Releases 30
Jul 01, 2011: Merck Receives Approval To Market GARDASIL In Japan 30
Apr 26, 2011: Merck Receives Health Canada Approval For Gardasil For Women Up To Age 45 30
Apr 06, 2011: U.S. Prescribing Information for GARDASIL Updated; Indication Not Granted for Use in Adult Women 31
Oct 16, 2009: FDA Approves GARDASIL for Use in Boys and Young Men 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Vaginal Cancer, H2 2012 7
Products under Development for Vaginal Cancer – Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Assessment by Monotherapy Products, H2 2012 13
Assessment by Combination Products, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 16
Assessment by Stage and Molecule Type, H2 2012 18
Vaginal Cancer Therapeutics – Discontinued Products 28
Vaginal Cancer Therapeutics – Dormant Products 29

List of Figures
Number of Products under Development for Vaginal Cancer, H2 2012 7
Products under Development for Vaginal Cancer – Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 13
Assessment by Combination Products, H2 2012 14
Assessment by Route of Administration, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 16
Assessment by Molecule Type, H2 2012 17
Assessment by Stage and Molecule Type, H2 2012 18

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos